Skip to main content
Fig. 1 | Journal of Biomedical Science

Fig. 1

From: MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway

Fig. 1

miR-138-1-3p expression was reduced in sorafenib-resistant cells and may participate in resistance development. A 50% inhibitory concentration (IC50) measured by CCK-8 assay at different concentration of sorafenib over 48 h. B Twenty-nine miRNAs exhibited significantly different expression between the two groups by Heat map from RNA sequencing. six candidates: miR-340-3p, miR-138-1-3p, miR-129-5p, miR-124-3p, miR-143-3p and miR-374a-5p were reduced in HepG2-SR cells; C Expression of the six candidates in the resistant cell lines detected by qRT-PCR. D Cell viability measured by CCK-8 assay of the resistant cell lines after transfected with six nominated miRNAs mimics, treating with sorafenib (10 μM, 48 h). miR-138-1-3p consistently suppressed resistant cell proliferation. E The expression of miR-138-1-3p in tumor tissues and adjacent normal tissues from 40 HCC patients was tested by qRT-PCR

Back to article page